News

As of April 15, Opsynvi (macitentan and tadalafil) — the first single-tablet treatment combination approved by the U.S. Food and Drug Administration (FDA) for pulmonary arterial hypertension (PAH) — is available to eligible patients in the U.S. through a specialty pharmacy network. With its launch, PAH patients who…

Despite more women being affected by pulmonary hypertension (PH), men with the cardiovascular disease had worse right ventricular function and lower odds of transplant-free survival relative to their female counterparts, a study found. In a large group of patients with various types of PH, sex differences in function of…

Most people with pulmonary arterial hypertension (PAH) due to connective tissue disease (CTD) who are using Opsumit (macitenan) do so as part of a combination therapy, according to real-world evidence from two U.S. drug registry studies. Its safety and effectiveness, in terms of clinical outcomes, for these patients…

The American Kidney Fund (AKF) has awarded an early-career fellowship that will support new research aiming to understand how pulmonary hypertension (PH) develops in people with chronic kidney disease. The project will be led by Marcelle Tuttle, MD, a first-year fellow at the Tufts Medical Center division of…

Note: This story was updated April 11, 2024, to remove reference to Acceleron Pharma, now a wholly owned subsidiary of Merck.  Winrevair (sotatercept-csrk), the under-the-skin injectable treatment recently approved in the U.S. for adults with pulmonary arterial hypertension (PAH), is expected to be available…

Having pulmonary hypertension (PH) worsens the likelihood of potentially life-threatening cardiac and respiratory complications in people with human immunodeficiency virus (HIV) infection, a U.S. database study reported. Its findings “can inform clinical practice and help healthcare providers make more informed decisions regarding the screening, diagnosis, and management of PH…

Inhibikase Therapeutics is meeting with the U.S. Food and Drug Administration (FDA) April 5 to discuss the potential of its experimental formulation of imatinib, dubbed IkT-001Pro, for pulmonary arterial hypertension (PAH). “Following our … discussion with the FDA related to the path to approval for IkT-001Pro in up…

A slit lamp exam of the eyes may detect signs that could help doctors predict how well treatment will work in people with pulmonary arterial hypertension (PAH) associated with systemic lupus erythematosus (SLE), an autoimmune disease, a small study suggests. Specific eye signs can also help evaluate PAH progression…

Enrollment has begun in a Phase 1b study of Tectonic Therapeutic’s TX45, an investigational treatment for people with pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF). TX45 is a long-acting formulation of relaxin, a protein involved in reproduction and cardiovascular function. It has anti-fibrotic, or anti-scarring,…

The U.S. Food and Drug Administration (FDA) has approved the under-the-skin injection therapy sotatercept-csrk — to be marketed under the brand name Winrevair — to treat adults with pulmonary arterial hypertension (PAH). The now-approved treatment is expected to be available for dispensing by select U.S. specialty pharmacies by the…

The U.S. Food and Drug Administration (FDA) has approved once-daily, fixed-dose tablets containing a combination of macitentan and tadalafil — to be marketed under the brand name Opsynvi — to treat adults with pulmonary arterial hypertension (PAH). The approval marks the first single-tablet treatment combination to become available…

Blood levels of microRNA — small RNA molecules that regulate protein production — are decreased in people with pulmonary embolism (PE) compared with healthy people. PE is the cause of chronic thromboembolic pulmonary hypertension (CTEPH). However, higher blood levels of miR-let7a were found in people with acute PE who…